You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Selective CYP26 inhibitors for the oral treatment of recalcitrant nodular acne.

    SBC: DERMAXON LLC            Topic: NIAMS

    Project Summary / Abstract DermaXon's project goal is to develop efficacious, substrate-based, selective inhibitors of CYP26s, the enzymes responsible for the metabolism of all-trans retinoic acid (atRA) in the epidermis, as an oral treatment for severe recalcitrant acne. This approach will provide an improved acne therapeutic without the adverse effects associated with currently marketed retinoid ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Pharmacogenomics Workflow: Identifying Biomarkers and Treatment Options

    SBC: Golden Helix, Inc.            Topic: 172

    Abstract Pharmacogenomics, the study of how an individual's genetic makeup affects their response to drugs, has undergone rapid advancements. This has occurred alongside a decrease in the cost of genotyping technology, making implementation of pharmacogenomics into clinical practice increasingly feasible. Personalized medicine leveraging pharmacogenomics is gaining momentum to optimize drug choice ...

    SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Booth™ by Opio™: Developing technology to expand the reach of opioid treatment programs into rural and underserved areas.

    SBC: Opio Connect, Inc.            Topic: NIDA

    The goal of this project is to develop a treatment booth with technology that allows opioid treatment programs to remotely dispense, either methadone or buprenorphine, under medical observation through telemedicine to a patient in a treatment booth. We believe that robotic automation is the ideal application to perform the same mechanical functions of the nurse at the dosing window. Specifically, ...

    SBIR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. PCR-based miRNA assessment of neonatal opioid withdrawal syndrome (NOWS) severity

    SBC: FYR Diagnostics, LLC            Topic: NIDA

    Abstract Opioid use disorder (OUD) has become a national crisis, affecting over 2 million Americans. The number of pregnant women with OUD in the U.S. increased almost 5-fold in the past decade, leading to a similar surge in infants born with neonatal opioid withdrawal syndrome (NOWS), from 1.5 to 8 per 1,000 hospital births (32,000 cases total) between 2004 and 2014. Associated hospital costs hav ...

    SBIR Phase I 2021 Department of Health and Human ServicesNational Institutes of Health
  5. An optimized screening platform for identifying and quantifying biased agonists as drugs for the treatment of Opioid Use Disorder

    SBC: MONTANA MOLECULAR LLC            Topic: NIDA

    ! Project Summary Millions of Americans today have an opioid use disorderOUDMillions more misuse opioidsand the crisis continues to growThe goal of this proposal is to speed the discovery of non addictive analgesics by providing drug discovery teams with simplermore robustmore quantitativeassays for agonist biasDriven by the urgency of the problem we are seeking Fast Track support to create new as ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. Developing EXP-1801 as an imaging agent to quantify pain and analgesia

    SBC: Expesicor Inc            Topic: NINDS

    Summary Abstract There are currently no tools available that can objectively measure painHistoricallypain in humans has been measured using subjective ratings to determine presence and severityIn animal modelspain is measured by semi quantitative assays that rely on the observation of pain behaviorsThough usefulthe inherently subjective nature of these measures has hampered both research and treat ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Topical selective T-type blockers for the treatment of pruritus

    SBC: DERMAXON LLC            Topic: NIAMS

    Project SummaryAbstractPruritusalso called itchis the most frequent dermatological symptom in the US with up toof Americans being affectedPruritic stimuli are detected by a subset of nociceptive neuronspruriceptorswhich fire action potential in response to peripheral activation by THor THmolecules induced by chronic inflammatory skin diseases such as ichthyosisprurigo nodularisand hidradenitis sup ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  8. Project isoPTE: isothermic post-traumatic epilepsy miRNA biomarker detection

    SBC: FYR Diagnostics, LLC            Topic: 999

    Project Summary Acquired epilepsy results from acute brain injury, such as traumatic brain injury (TBI). Acquired epilepsy is a major public health issue with inadequate treatment and diagnostic options. There are no biomarkers that assist in the prediction or diagnosis of acquired epilepsy. Project isoPTE will use two animal models of epilepsy to determine whether plasma microRNA (miRNA) biomarke ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  9. Modeling drug-refractory epilepsy with the KaL method

    SBC: Expesicor Inc            Topic: NINDS

    Epilepsy is a common neurological disorder that is characterized by recurrentspontaneousseizuresEpilepsy is a major public health issue with inadequate treatment optionsOvermillion people worldwide have epilepsyThis is more than cerebral palsymultiple sclerosisandParkinson s disease combinedAlthough more than two dozen antiseizure drugsASDsexistapproximately one third of patientsovermillionsuffer ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  10. Discovery of NaV1.7 Inhibitors for the Treatment of Pain

    SBC: SITEONE THERAPEUTICS, INC.            Topic: 105

    PROJECT SUMMARY The objective of our program is to develop a safe and effective nonopioid analgesic for the treatment of neuropathic pain, such as pain associated with chemotherapy-induced peripheral neuropathy, that targets an isoform of the voltage-gated sodium ion channel, NaV1.7. Voltage-gated sodium channels are involved in the transmission of nociceptive signals from their site of origin in ...

    SBIR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government